Cervical Cancer

Oncology·MeSH: Uterine Cervical Neoplasms

Prevalence

18.0 / 100K

Incidence

7.5 / 100K/yr

35 drugs in development·10 companies·60 clinical trials

Drug Pipeline by Phase

Approved(1)

Drug	Company
Aybintio (SB8)	Organon & Co. (OGN)

Phase 3(17)

Drug	Company
5-fu	ASTRAZENECA PLC (AZN)
AXAL (axalimogene filolisbac / ADXS-HPV)	Ayala Pharmaceuticals, Inc. (ADXS)
Background Chemotherapy	Merus N.V. (MRUS)
cobolimab	ANAPTYSBIO, INC (ANAB)
Dostarlimab	ANAPTYSBIO, INC (ANAB)
Dostarlimab and TSR-022	ANAPTYSBIO, INC (ANAB)
First-line Chemotherapy	Merus N.V. (MRUS)
Lymphodepleting chemotherapy	Merus N.V. (MRUS)
Rescue Medications	Merck & Co., Inc. (MRK)
Rescue medications for chemotherapy	Merus N.V. (MRUS)
Single-agent chemotherapy	Merus N.V. (MRUS)
timing to initiate the adjuvant FOLFOX chemotherapy	Merus N.V. (MRUS)
Tisotumab Vedotin	Merck & Co., Inc. (MRK)
topotecan	PFIZER INC (PFE)
Topotecan	Merck & Co., Inc. (MRK)
vinorelbine	PFIZER INC (PFE)
Vinorelbine	Merck & Co., Inc. (MRK)

Phase 2(2)

Drug	Company
agen1884	AGENUS INC (AGEN)
agen2034	AGENUS INC (AGEN)

Early Phase 1(1)

Drug	Company
hb-201 iv	HOOKIPA Pharma Inc. (HOOK)

Phase 1/Phase 2(2)

Drug	Company
bms-936558-01	BRISTOL MYERS SQUIBB CO (BMY)
tisotumab vedotin	PFIZER INC (PFE)

Phase 4(12)

Drug	Company
bms-986340	BRISTOL MYERS SQUIBB CO (BMY)
CAPOX chemotherapy	Merus N.V. (MRUS)
Chemotherapy Regimen	Merus N.V. (MRUS)
Concurrent chemotherapy	Merus N.V. (MRUS)
Conditioning chemotherapy	Merus N.V. (MRUS)
FOLFOX chemotherapy	Merus N.V. (MRUS)
Investigator's Choice of Chemotherapy	Merus N.V. (MRUS)
Lymphodepletion Chemotherapy	Merus N.V. (MRUS)
Platinum chemotherapy	Merus N.V. (MRUS)
Single Cycle Intensive Chemotherapy	Merus N.V. (MRUS)
Tandem 3 Cycle Intensive Chemotherapy	Merus N.V. (MRUS)
tivdak	PFIZER INC (PFE)

BioSniper tracks 35 drugs in development for Cervical Cancer across 10 companies.

There are 60 clinical trials targeting Cervical Cancer tracked by BioSniper.

The estimated prevalence of Cervical Cancer is approximately 18.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.